Nonsquamous Nonsmall Cell Neoplasm of Lung
Conditions
Keywords
First line treatment, Non small cell lung cancer, non squamous
Brief summary
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
Detailed description
This is a observational study prospectively followed post-authorization.
Interventions
DRUGpaclitaxel, carboplatin and bevacizumab
Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
Sponsors
Spanish Lung Cancer Group
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients should sign inform consent before inclusion in the study that specifies that the clinical treatment entails consent for the analysis of biological samples of tumor and blood. 2. Histologically confirmed diagnosis of advanced non small-cell lung carcinoma, non-squamous cell 3. Patients age 18 years or more 4. Patients will be candidates to received a first line of chemotherapy of carboplatin, paclitaxel and bevacizumab as the best therapeutic option. 5. Evidence of measurable disease per Response Evalutation Criteria in Solid tumors (RECIST) 6. Patients must be avalaible for clinical follow-up 7. Patients with the following hematologic/biochemical values: * Absolute Neutrophil Count ANC \> 1500/µl. * Platelets \> 100.000 /µl. * Hemoglobine \> 10 g/dl. * Bilirrubin \< 1.5 mg/dl. * Aspartate aminotransfereasa (AST) and Alanine transaminase (ALT) ≤ 3 x LSN, except in case of hepatic metastases: upper 5 x LSN * Creatinine clearance ≥ 45 ml/min.
Exclusion criteria
1. Previous treatment for advanced disease. Chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neadjuvant treatment 2. history of haemoptysis (defined as at least half a teaspoon's emission of red blood) in the 3 months prior to inclusion 3. evidence by CT of tumor cavitations, or tumours invading or abutting major blood vessels 4. Known or suspected brain metastases non-treated. 5. Major surgery within 28 days of starting treatment. 6. Minor surgery within 24 hours before starting the treatment. 7. Non-controlled hypertension (systolic \> 150 mm Hg and/or diastolic \> 100 mm Hg). 8. Patients with coronary disease or uncontrolled arrhytmia, uncontrolled cerebrovascular disease and other clinical conditions that, in judgment of the investigator, contraindicate the patient's participation in the study. 9. History or evidence of bleeding diathesis or hereditary coagulopathy. 10. Contraindication or suspected allergy to the products under investigation in the study:: paclitaxel, carboplatine or bevacizumab. 11. Patients who are pregnant or breasfeeding. Women of childbearing potencial must have a negative pregnancy test performed within 7 days before the onset of treatment. 12. Substance abuse of clinical, psychological or social conditions that can undermine the validity of the informed consent or protocol compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between angiogenesis markers and progression free survival. | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Overal survival | 3 year |
| Survival at 12 and 24 months | 12-24 months |
| Objective response | 24 months |
| Duration of response | 24 months |
| Treatment security | 24 months |
Countries
Spain
Outcome results
None listed